An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder by Athanasopoulos, Anastasios & Giannitsas, Konstantinos
Hindawi Publishing Corporation
Advances in Urology
Volume 2011, Article ID 820816, 8 pages
doi:10.1155/2011/820816
Review Article
An Overview of the Clinical Use of Antimuscarinicsin
the Treatment of Overactive Bladder
AnastasiosAthanasopoulos andKonstantinos Giannitsas
Urodynamic Urology Unit, Department of Urology, Medical School, University of Patras, 26500 Patra, Greece
Correspondence should be addressed to Anastasios Athanasopoulos, tassos athan@hotmail.com
Received 26 February 2011; Accepted 13 April 2011
Academic Editor: Yasuhiko Igawa
Copyright © 2011 A. Athanasopoulos and K. Giannitsas. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical
treatment of overactive bladder. They oﬀer signiﬁcant improvements in symptoms and patients’ quality of life. Antimuscarinics
are generally well tolerated with mild and predictable side eﬀects. Available antimuscarinics have small, yet statistically signiﬁcant,
diﬀerencesintheireﬃcacyandtolerabilityproﬁles.Inclinicalpractice,ﬁndingtheagentthatoﬀerstheoptimumbalanceofeﬃcacy
and side eﬀects for an individual patient remains the major challenge.
1.Introduction
Overactive bladder (OAB) is a lower urinary tract condition,
characterized by symptoms of urgency, with or without urge
incontinence, usually with frequency and nocturia. This
symptom complex signiﬁcantly aﬀects patient’s quality of
life. In most cases, the underlying pathophysiology is an
involuntary detrusor contraction during the storage phase
of the voiding cycle [1].
Normal bladder contraction during voiding involves
stimulation of the muscarinic receptors on the detrusor
muscle by acetylcholine (Ach). The role of Ach in the
pathogenesis of involuntary contractions during the storage
phase is elusive. Despite the fact that detrusor may contract
spontaneously, as a result of the intrinsic activity of the
m y o c y t eo ro fs m a l lu n i t so fs m o o t hm u s c l ec e l l s[ 2], Ach is
stillreleasedfromthenervesorfromnonneurogenicsources,
like the urothelium. A direct or indirect eﬀect of Ach should
be considered [2]. Muscarinic receptors are also found on
the presynaptic nerve terminals to the bladder participating
in the regulation of transmitter release. Currently, there
is increasing evidence for an important role of aﬀerent
pathways in the pathophysiology of involuntary detrusor
contractions[2,3].Antimuscarinics,whichblockmuscarinic
receptors, have been the treatment of choice for overactive
bladder for decades. They aﬀect the eﬀerent control on
detrusor contraction, but increasing evidence also suggests
ar o l ei na ﬀerent pathways’ regulation.
There are several subtypes of muscarinic receptors. The
human detrusor contains mainly the M2 and M3 subtypes
[4]. Available antimuscarinics vary in their selectivity for
muscarinic receptors.
Oxybutynin [5–8], Tolterodine [9], propiverine [10],
solifenacin [11, 12], darifenacin [13, 14], trospium [15, 16],
andfesoterodine[17]areantimuscarinicagentsapprovedfor
use in OAB treatment. Evidence on the eﬃcacy and safety of
these agents as a class is reviewed here, and issues concerning
their clinical application are discussed.
2.MaterialsandMethods
The current literature on the eﬃcacy and safety of antimus-
carinics was reviewed by searching Medline/PubMed for
relevant articles, published in English between 1980 and
2010.
3. Results and Discussion
3.1. Antimuscarinics
3.1.1. Oxybutynin. Oxybutynin is the ﬁrst antimuscar-
inic used for the treatment of OAB. In addition to its2 Advances in Urology
antimuscarinic action, oxybutynin in high doses exerts
muscle-relaxant and local anaesthetic eﬀects [5–8].
Oxybutynin is now available in oral, immediate (IR)
and extended release (ER), as well as two transdermal
formulations, a patch and a gel. An intravesical formulation
of oxybutynin has also been studied [18].
Oxybutynin IR formulation was the ﬁst that entered
clinical practice. Despite its satisfactory eﬃcacy, the substan-
tial incidence of dry mouth, immediate release oxybutynin’s
most common and bothersome side-eﬀect, limited its tol-
erability. Newer formulations aimed at eliminating peaks in
concentration of oxybutynin and its metabolites in order to
reduce related side eﬀects.
The ER formulation of oxybutynin provides a smooth
plasma concentration proﬁle over the 24-hour dosage inter-
val, facilitating once-daily administration. Hence, given its
overall eﬃcacy/tolerability and dose ﬂexibility, oxybutynin
ER provides an alternative in the ﬁrst line of pharmacother-
apy for OAB [8]. Overall, as shown in the OPERA study [19],
oxybutynin ER has modestly greater eﬃcacy than tolterodine
ER at its most commonly prescribed dose. In the OBJECT
study, oxybutynin ER was more eﬀective than tolterodine IR
at the endpoints of urge incontinence, total incontinence,
and micturition frequency episodes [20].
The transdermal oxybutynin (OXY-TDS) formulation
oﬀers patients with urinary incontinence an eﬀective, safe
and well-tolerated option for managing the symptoms of
overactive bladder [7, 21]. As OAB contributes to decreased
work productivity due to job interruptions as well as fatigue,
theuseofOXY-TDSmayresultinproductivityimprovement
when patients receive 3.9mg/day via twice weekly patch
application for up to 6 months [22].
Oxybutynin chloride topical gel (OTG) was approved
in January 2009 by the US FDA. OTG was designed to
provide steady plasma oxybutynin levels with daily applica-
tion, favorably altering the circulating N-desethyloxybutynin
metabolite to oxybutynin ratio, thus minimizing the
antimuscarinic adverse eﬀects of oral formulations. The
use of a biocompatible delivery system also reduced the
application-siteskinreactionsassociatedwithotheravailable
formsoftransdermaldelivery.OTGrepresentsaneﬃcacious,
safe, and convenient alternative to other oxybutynin formu-
lations and oral antimuscarinics for the treatment of OAB
[23].
Interestingly, all the above-mentioned oxybutynin for-
mulations have been shown to be more eﬃcacious than the
IR oxybutynin [24, 25] in respective trials.
3.1.2. Tolterodine. Tolderodine is a widely prescribed anti-
muscarinic and, it was the ﬁrst speciﬁcally developed to treat
OAB. Tolterodine is not selective for any muscarinic receptor
subtype, but it exhibits selectivity for the urinary bladder
over salivary glands in vivo [26].
An IR formulation was available ﬁrst, but an ER,
administered once daily, formulation was later designed. Its
eﬃc a c ya n dt o l e r a b i l i t yh a v eb e e np r o v e di nal a r g en u m b e r
of trials [27]. Tolterodine oﬀers signiﬁcant improvement in
overactive bladder symptoms and quality of life while having
afavorablesafetyproﬁle.Itsoonbecamethegoldstandardin
the class, a drug that all others are compared to, during their
clinical development.
Oxybutynin and tolterodine, the until relatively recent
years most commonly prescribed antimuscarinics, have been
shown to have similar eﬃcacies in general OAB populations
[28], as well as in speciﬁc subpopulations deﬁned by severity
of urodynamic ﬁndings [29].
3.1.3. Propiverine. Propiverine, another muscarinic receptor
antagonist, has also been demonstrated to inhibit L-type
Ca++ channels in high concentrations [30].
Propiverine has similar eﬃcacy to oxybutynin and tolte-
rodine, similar tolerability and impact on quality of life to
tolterodine, but a better tolerability proﬁle than oxybutynin
[31, 32]. This drug is well tolerated [33].
Propiverine and oxybutynin are eﬃcacious in children
with incontinence due to overactive bladder and propiverine
is oﬃcially approved in certain countries for pediatric use.
Alloussi et al. [34] evaluated existing evidence for the use
of antimuscarinics in children. They concluded that high-
quality studies are still limited and results vary widely across
antimuscarinics. This fact is associated with diﬀerent levels
of evidence and grades of recommendation for children for
oxybutynin (3 C), propiverine (1B/C), tolterodine (3 C),
and trospium chloride (3 C), awarded by the International
Consultation on Incontinence. The daily urgency episodes
were signiﬁcantly reduced from baseline to 12 weeks on
propiverine treatment, compared with placebo. Secondary
endpoints, including sum of urgency severity per 24h,
urgency severity per void, and daytime voiding frequency,
were also improved signiﬁcantly in the propiverine group
[35].
3.1.4. Darifenacin. Darifenacin is the antimuscarinic with
the highest M-3 receptor subtype selectivity. Long-term
darifenacin treatment was associated with signiﬁcant and
clinically meaningful improvements in quality of life of
patients with urge incontinence (“wet” OAB) over 2 years
[36]. In a study of patients who were dissatisﬁed with their
previous treatment with oxybutynin ER or tolderodine ER,
patients perception of bladder condition (PPBC) score and
OABsymptomsweresigniﬁcantlyimproved,andsatisfaction
was high during treatment with darifenacin 7.5 or 15mg
[37]. Haab [14] in a comprehensive review described the
good clinical eﬃcacy and safety proﬁle of this agent.
3.1.5. Solifenacin. A pooled analysis of four randomized,
placebo-control1ed, phase III studies of solifenacin in
OAB patients without incontinence, showed a signiﬁcant
improvement of symptoms and voided volume after 12
weeks of treatment [38].
How does solifenacin compare to longer established
antimuscarinics? One comparison of the “new” (solifenacin
anddarifenacin)and“old”antimuscarinicagentsshowedthe
two generations of treatment had similar eﬃcacy [35, 39].
A randomized, double-blind study found that solifenacin is
superior to an encapsulated formulation of tolterodine ER
in most of the eﬃcacy outcomes [40]. The majority of side
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more for solifenacin, and discontinuations were comparable
and low in both groups. This study investigated both
approved doses of solifenacin, 5mg and 10mg, and was,
therefore, criticized for using doses not directly comparable
to tolterodine 4mg. A subanalysis of this study [30]s u b -
sequent compared solifenacin 5mg and tolderodine 4mg
and better reﬂected treatment outcomes with the doses most
commonly used in clinical practice, at least during treatment
initiation.Itconcludedthataftera4-weekstreatmentperiod,
solifenacin 5mg signiﬁcantly improved incontinence symp-
toms and reduced the use of incontinent pads, compared
to tolterodine. In another, randomized, placebo-controlled
study, Cardozo et al. [41] found that solifenacin signiﬁcantly
reduced the number of urgency episodes and urgency bother
andwaswelltolerated.Treatmentwaseﬀectiveasearlyasday
3.
Solifenacin is the ﬁrst antimuscarinic to demonstrate
signiﬁcant warning-time improvement in a large OAB
clinical trial conducted to evaluate warning time and diary
variables in the same study population [42].
A relatively recent comprehensive review for solifenacin
concluded that this agent was eﬀective in the treatment of
OAB with urge incontinence [12].
3.1.6. Trospium. Trospium chloride is a quaternary ammo-
nium compound. It does not cross the blood-brain bar-
rier; therefore, no central nervous system adverse events
are anticipated [16]. This drug signiﬁcantly reduces UUI
and frequency compared with placebo [43]. Compared
to tolderodine, trospium reduced the frequency of mic-
turition and incontinence episodes. Extended-release tro-
spium chloride 60mg, a novel modiﬁed-release form of
this compound allows once-daily administration, potentially
enhancing compliance to treatment and improving its clin-
ical eﬃcacy/tolerability proﬁle, compared with immediate-
release form [44]. Cardozo et al. [44] in a recent publication
underlined that the extent of metabolism of this drug
is low and independent of the liver cytochrome P450
isoenzyme system. This pharmacodynamic proﬁle further
simpliﬁes decision making in polypharmacy situations, such
as multimorbid and elderly patients. Furthermore, subject
to predominantly renal elimination as the unchanged form,
trospium chloride retains its pharmacological activity within
the urinary bladder, and local action on urothelium mus-
carinic receptors is supposed to contribute to its early onset
a n ds u s t a i n e de ﬃcacy in controlling urgency.
3.1.7. Fesoterodine. Fesoterodine is the newest antimus-
carinic for the treatment of OAB. Fesoterodine is a pro-
drug. It is rapidly and extensively hydrolyzed by non-
speciﬁc esterases, thus bypassing the CYP system, to 5-
hydroxymethyl tolderodine (5-HMT), which is also the
activemetaboliteoftolderodine.Interestingly,as5-HMTfor-
mation from fesoterodine occurs via ubiquitous nonspeciﬁc
esterases, the rate of fesoterodine hydrolyzation maybe more
uniform and complete.
Initial data from phase 2 trials showed that fesoterodine
was an eﬀective and well-tolerated therapy for OAB [45].
In subsequent clinical studies, fesoterodine doses of 4 and
8mg/day were consistently superior to placebo in improving
overactive bladder symptoms, with 8 mg/day having signif-
icantly greater eﬀects than 4mg/day [17]. Both doses were
safeandwelltolerated,withalowoverallincidenceofadverse
events. Tolerability is comparable to that of tolderodine (ER)
[46].
In a posthoc analysis of pooled data from two clinical
trials including 1,548 women with overactive bladder, fes-
oterodine 4mg and 8mg and tolderodine showed signiﬁcant
improvements in all bladder diary variables assessed and
greater response rates versus placebo. Fesoterodine 8mg was
signiﬁcantly more eﬃcacious than fesoterodine 4mg and
tolderodine ER in improving UUI episodes and continence
days per week [47]. Recently, the FACT study, a head
to head placebo controlled trial, compared the eﬃcacy
and tolerability of fesoterodine 8mg with tolderodine ER
4mg. This study was designed to asses the superiority
of fesoterodine over tolderodine ER for the treatment of
OAB symptoms, and 1697 patients were included. This trial
concluded that in patients with OAB, fesoterodine 8mg
showed superior eﬃcacy over tolderodine ER 4mg and
placebo in reducing UUI episodes and in improving most
patient-reported outcome measures. Both active treatments
were well tolerated [48]. In another recent study, the ﬂexible
dose of fesoterodine was evaluated. Among 516 subjects
treated, approximately 50% opted for dose escalation to
8mg at week 4. The study concluded that ﬂexible dose
fesoterodine signiﬁcantly improved OAB symptoms health
related quality of life (HRQOL) and rates of treatment
satisfaction and was well tolerated in patients with OAB who
were dissatisﬁed with prior tolderodine therapy [49].
3.2. Eﬃcacy and Safety. Currently available antimuscarinics
have all demonstrated their eﬃcacy and safety in well-
designed, controlled studies conducted during their clinical
development. The signiﬁcant placebo eﬀectobserved in OAB
trials and the frequent treatment discontinuations in real-life
practice have often raised doubts regarding the true eﬃcacy
and/or safety of this drug class. Systematic reviews and meta-
analyses of existing data have tried to clarify uncertainties.
In 2003, Herbison et al. [39] have published a systematic
review of randomized controlled trials comparing antimus-
carinic agents to placebo in the treatment of OAB. The
authors concluded that antimuscarinic drug therapy pro-
vided signiﬁcant improvement in OAB symptoms, such as
urge incontinence episodes and micturition frequency over
placebo. Signiﬁcant improvements, compared to placebo
have also been demonstrated for urodynamic parameters.
However, the magnitude of treatment eﬀect was smaller than
the anticipated based on clinical experience with antimus-
carinics. A possible explanation for this is the common
combination of medical treatment and bladder training in
clinical practice. In the majority of clinical trials, formal
bladder training is not included.
A 2005 systematic review of 52 randomized, controlled
trials by Chapple et al. [50], which was latter updated with
more studies in 2008 [51], showed that antimuscarinics,
as a class, signiﬁcantly reduce urge incontinence episodes,
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improvements in quality of life. They also reduce the severity
of urgency and decrease micturition frequency. Individual
antimuscarinics were eﬀective in at least one of the outcome
measures included in the reviews. Proﬁles of each drug and
dosage diﬀer and should be considered in making treatment
choices. Despite abundance of evidence on the short-term
eﬃcacy of antimuscarinics, Chapple et al. noted a lack of
knowledge regarding issues of chronic treatment, given that
followup in most trials is short.
Diﬀerences in eﬃcacy of antimuscarinics have often
reached statistical signiﬁcance in clinical trials. Nevertheless,
the magnitude of these diﬀerences is not readily appreciated
in everyday clinical practice and many clinicians consider
drugs in this class as “comparable” in terms of eﬃcacy.
According to a meta-analysis by Novara et al. [24], eﬃcacies
of available antimuscarinics are comparable. Nevertheless,
if factors such as safety, tolerability, and cost are to be
taken into account, Oxybutynin ER, tolterodine ER 4mg,
solifenacin 5mg, or solifenacin 10mg can be considered
the ﬁrst-line treatment choice. Darifenacin 15mg and
fesoterodine 4mg are alternatives although more data are
needed. In cases of lack of eﬃcacy of ﬁrst-line ER drug,
fesoterodine 8mg and solifenacin 10mg might be second-
line treatment, given that their eﬃcacy is superior with only
a small compromise in tolerability.
As far as safety is concerned, antimuscarinics, in general,
are safe [24, 52, 53]. The “older” drugs oxybutynin and
tolterodine have been more thoroughly studied [54, 55].
Side eﬀects are due to muscarinic receptor binding in organs
other than the bladder. The eﬀects of antimuscarinics on
salivary glands are responsible for the most common and
bothersome side eﬀect, dry mouth. Other unwanted eﬀects
include constipation, blurred vision, somnolence, dizziness
and cognitive impairment. Untreated, close-angle glaucoma
is a contraindication for antimuscarinics.
Slight diﬀerences in the safety proﬁles of existing anti-
muscarinic agents depend on their selectivity for speciﬁc
muscarinic receptor subtypes, selectivity for the bladder
compared to salivary glands, their lipophilicity and ability to
cross the blood-brain barrier, as well as their pharmacoki-
netic properties.
Evidence from controlled trials [50] suggests that anti-
muscarinics are well tolerated compared with placebo,
with the exception of immediate-release (IR) oxybutynin.
Extended-release (ER) tolterodine is the only formula-
tion with fewer total treatment discontinuations com-
pared with placebo, a ﬁnding that just reached statistical
signiﬁcance.
In general, the extended release formulations are better
tolerated than the immediate release ones. In cases that dry
mouth is intolerable with the oral formulations, transder-
mal oxybutynin might bean alternative, but, unfortunately,
application site reactions are common with the oxybutynin
patch [21]. Solifenacin and darifenacin are believed to be
associatedwithhigherratesofconstipation[24]comparedto
other antimuscarinics. Nevertheless, a recent meta-analysis
of randomized, placebo-controlled trials has shown high
odds ratios for constipation, compared with placebo, for
other drugs as well [56].
Central nervous system side eﬀects are a concern when
prescribing antimuscarinics for the treatment of OAB,
particularly in vulnerable populations such as the elderly
and CNS-compromised, neurogenic bladder patients. The
evidence for cognitive impairment with oxybutynin is com-
pelling [57]. Darifenacin with low CNS penetration and
selectivity for the M3 over the M1 muscarinic receptor
subtype is expected to cause less cognitive impairment.
Indeed, in a short term study, darifenacin did not have any
eﬀect on the cognitive function [58]. Moreover, a review
of available literature [59] concluded that darifenacin did
not cause an impairment of memory among other cognitive
functions. Trospium chloride is another drug that does
not cross the blood-brain barrier and in a recent study
it was undetectable in the older human central nervous
system [60]. Fesoterodine is considerably less lipophilic than
tolderodine [61] which has minimal or no cognitive eﬀects.
The binding of muscarinic receptors in the heart may
lead to cardiovascular adverse events and QT interval
prolongation has been a concern with antimuscarinics. In
a randomized, double-blind, placebo-controlled, crossover
trial [62], tolterodine signiﬁcantly increased heart rate
versus placebo and darifenacin did not aﬀect heart rate
compared to placebo. Darifenacin does not prolong QT/QTc
interval [63]. An older study showed that Oxybutynin is not
associated with a corrected QT interval prolongation and
is unlikely to induce ventricular arrhythmias [64]. It seems
that tolterodine does not have a clinically signiﬁcant eﬀect
on QT interval [65]. Propiverine provoked a statistically
signiﬁcant increase in the mean QTc interval but without
clinical arrhythmic events [66]. The newest antimuscarinic
drug fesoterodine is not associated with QTc prolongation
or other ECG abnormalities at either therapeutic or supra-
therapeutic doses [67]. In a study with real-life conditions,
that is, with inclusion of large numbers of patients with
cardiovascular comorbidities and taking several other medi-
cations, therapeutically eﬀective doses of solifenacin did not
increase heart rate or blood pressure [68].
3.3. Special Treatment Issues
3.3.1. Treatment Compliance. Despite acceptable rates of
treatment discontinuation in clinical trials, real-life compli-
ance, especially to long-term treatment, is low. For example,
in a pharmacy dispensing records review for antimuscarinic
agents from January 2003 to December 2006 conducted for
the United States Military Health System National Capital
Region, 35% of OAB patients did not reﬁll a fullyreimbursed
prescription for antimuscarinics [69]. In another study,
44.5% of patients did not renew their ﬁrst prescription of
antimuscarinics [70]. In observational trials, under real-
life conditions, discontinuation rates for tolterodine, for
example,havebeenreportedtobeashighas49%at6months
followup [71]. Overall, adherence is signiﬁcantly better for
extended release than immediate release agents.
Low compliance to treatment can be due to inadequate
drug eﬃcacy, intolerable side eﬀects, poor patient education
and follow up, and cost issues. Among these reasons
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clinical practice, unmet expectations may represent another
important reason for treatment discontinuation [73, 74].
Selecting the appropriate drug for each patient, the one that
oﬀers the best balance between eﬃcacy and adverse events
would be a very important step in improving adherence to
treatment. Patient education on OAB and its treatments and
patient reassurance when side eﬀects occur represent other
important strategies in improving compliance. Realistic
patient expectations from treatment are a prerequisite for
treatment success.
3.3.2. Dose Flexibility. Dose ﬂexibility oﬀers the advantage of
an individually tailored treatment to achieve the optimum
balance between eﬃcacy and adverse events. A strategy
based on patient-requested dose increases has been found
to consistently improve overactive bladder symptoms. The
impactofdoseﬂexibilityonclinicalmanagementofOABhas
been examined in studies with solifenacin, darifenacin, and
oxybutynin ER [75]. Patients requesting a dose increase usu-
ally had more severe symptoms at baseline than those who
did not request uptitration. Patients with severe symptoms
at baseline beneﬁt more from the increased dose [75]. In
clinical trials, about 50% of the patients askforan increase of
the dose of their medication [40, 49]. Selecting a drug which
oﬀers dose ﬂexibility seams a reasonable ﬁrst-line treatment
approach.
3.3.3. Switch between Antimuscarinics. Despite the fact that
diﬀerences in eﬃcacy of antimuscarinics in clinical trials
with large OAB populations are relatively small, an indi-
vidual patient may beneﬁt more from a particular drug
than another. “Salvaging” nonresponders to one drug with
another has been shown in several studies. Solifenacin, for
example, has been shown to signiﬁcantly improve bladder
diary and validated quality-of-life outcomes in women with
urge incontinence that failed to respond or were unable
to tolerate oxybutynin IR [75]. Solifenacin treatment in
patients with residual urgency after an at-least-four-week
course of tolterodine ER 4mg was associated with signiﬁcant
improvements in urgency and other diary-documented
symptoms of OAB. Patients treated with solifenacin also had
signiﬁcant improvements in quality of life scores and the
perceived bother of OAB [76]. In another study, patient’s
perception of bladder condition (PPBC) score and OAB
symptoms were signiﬁcantly improved, and satisfaction
was high during treatment with darifenacin (7.5/15mg) in
patients who were dissatisﬁed with the previous oxybutynin
ER or tolterodine ER treatment [37]. In a recent study [77],
patients dissatisﬁed with tolterodine received fesoterodine
4mg or 8mg. PPBC, urgency perception scale and the
overactive bladder questionnaire (OAB-q) were signiﬁcantly
improved after 12 weeks of fesoterodine and 80% of patients
became satisﬁed.
The above studies, despite limitations in patient selection
and overall design, suggest that switch between drugs is a
reasonable approach in patient failing initial treatment.
3.3.4. Safety in the Male Population. A signiﬁcant concern
when antimuscarinics are considered in male patients with
storage lower urinary tract symptoms (LUTS), suggestive
of an overactive bladder, is the risk of urinary retention.
This concern seems particularly relevant when voiding,
benign prostate hyperplasia-related LUTS are present. The
reality, nevertheless, is that antimuscarinics at clinically
recommended doses have little eﬀect on voiding pressures.
Clinical experience has proved that concerns regarding
acute urinary retention or increased residual volume are
unfounded [78–83]. The incidence of urinary retention is
minimal (<1%), even in male patients with bladder outﬂow
obstruction, despite the occasional increase in residual
urine in certain patients. On the other hand, there are
no established criteria for excluding patients at risk for
retention from antimuscarinic therapy [81]. More studies
with large number of patients, including patients with
severe obstruction, are required. In the meantime, it seems
reasonable to oﬀer antimuscarinics, either as monotherapy
or in combination with α-blockers to men with mild-to-
moderate obstruction and small residual volumes. The
addition of an antimuscarinic to a-blockers has been shown
to signiﬁcantly improve symptoms and quality of life of
these patients [79, 81, 84, 85].
4. Conclusions
Antimuscarinic agents, as a class, are the cornerstone
of medical treatment of overactive bladder. Accumulated
evidence from clinical trials and meta-analyses has proved
their eﬃcacy and safety. Antimuscarinics oﬀer signiﬁcant
improvements in symptoms of urge incontinence, urgency,
frequency, and nocturia. This translates in substantial ben-
eﬁts in quality of life. Antimuscarinics are generally well
tolerated with mild and predictable antimuscarinic side
eﬀects. The most common and bothersome of them, dry-
mouth, not infrequently leads to treatment discontinuation.
Available antimuscarinics have small, yet statistically sig-
niﬁcant, diﬀerences in their eﬃcacy and tolerability proﬁles.
Ingeneral,thehigherdoses ofdrugsthatoﬀerdoseﬂexibility
have higher eﬃcacy. Tolerability depends mainly on drug
selectivity for the bladder over other organs, selectivity for
muscarinic receptor subtypes and ability to penetrate the
CNS. Given that there is no “cure” for OAB yet, ﬁnding the
agent that oﬀers the optimum balance of eﬃcacy and side
eﬀects for an individual patient remains the major challenge
in OAB treatment.
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